|
1
|
Bevers TB, Helvie M, Bonaccio E, Calhoun
KE, Daly MB, Farrar WB, Garber JE, Gray R, Greenberg CC, Greenup R,
et al: Breast cancer screening and diagnosis, version 3.2018, NCCN
clinical practice guidelines in oncology. J Natl Compr Canc Netw.
16:1362–1389. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Falzone L, Salomone S and Libra M:
Evolution of cancer pharmacological treatments at the turn of the
third millennium. Front Pharmacol. 9:13002018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Christofi T, Baritaki S, Falzone L, Libra
M and Zaravinos A: Current perspectives in cancer immunotherapy.
Cancers (Basel). 11:14722019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tong CWS, Wu M, Cho WCS and To KKW: Recent
advances in the treatment of breast cancer. Front Oncol. 8:2272018.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mustacchi G and De Laurentiis M: The role
of taxanes in triple-negative breast cancer: Literature review.
Drug Des Devel Ther. 9:4303–4318. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Telli M: Evolving treatment strategies for
triple-negative breast cancer. J Natl Compr Canc Netw. 13 (Suppl
5):S652–S654. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xu J, Wu KJ, Jia QJ and Ding XF: Roles of
miRNA and lncRNA in triple-negative breast cancer. J Zhejiang Univ
Sci B. 21:673–689. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mattick JS and Makunin IV: Non-coding RNA.
Hum Mol Genet. 15:Spec No: 1. R17–R29. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liz J and Esteller M: lncRNAs and
microRNAs with a role in cancer development. Biochim Biophys Acta.
1859:169–176. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Polo A, Crispo A, Cerino P, Falzone L,
Candido S, Giudice A, Petro GD, Ciliberto G, Montella M, Budillon A
and Costantini S: Environment and bladder cancer: Molecular
analysis by interaction networks. Oncotarget. 8:65240–65252. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Falzone L, Grimaldi M, Celentano E,
Augustin LSA and Libra M: Identification of modulated MicroRNAs
associated with breast cancer, diet, and physical activity. Cancers
(Basel). 12:25552020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Soudyab M, Iranpour M and Ghafouri-Fard S:
The role of long non-coding RNAs in breast cancer. Arch Iran Med.
19:508–517. 2016.PubMed/NCBI
|
|
13
|
Tian JB, Cao L and Dong GL: Long noncoding
RNA DDX11-AS1 induced by YY1 accelerates colorectal cancer
progression through targeting miR-873/CLDN7 axis. Eur Rev Med
Pharmacol Sci. 23:5714–5729. 2019.PubMed/NCBI
|
|
14
|
Zhang S, Jiang H, Xu Z, Jiang Y, She Y,
Huang X, Feng S, Chen W, Chen S, Chen Y, et al: The resistance of
esophageal cancer cells to paclitaxel can be reduced by the
knockdown of long noncoding RNA DDX11-AS1 through TAF1/TOP2A
inhibition. Am J Cancer Res. 9:2233–2248. 2019.PubMed/NCBI
|
|
15
|
Wu Z, Cai X, Huang C, Xu J and Liu A:
miR-497 suppresses angiogenesis in breast carcinoma by targeting
HIF-1α. Oncol Rep. 35:1696–1702. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tian F, Zhan Y, Zhu W, Li J, Tang M, Chen
X and Jiang J: MicroRNA-497 inhibits multiple myeloma growth and
increases susceptibility to bortezomib by targeting Bcl-2. Int J
Mol Med. 43:1058–1066. 2019.PubMed/NCBI
|
|
17
|
Liu Z, Wu S, Wang L, Kang S, Zhao B, He F,
Liu X, Zeng Y and Liu J: Prognostic value of microRNA-497 in
various cancers: A systematic review and meta-analysis. Dis
Markers. 2019:24912912019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Luo G, He K, Xia Z, Liu S, Liu H and Xiang
G: Regulation of microRNA-497 expression in human cancer. Oncol
Lett. 21:232021.PubMed/NCBI
|
|
19
|
Xu S, Fu GB, Tao Z, OuYang J, Kong F,
Jiang BH, Wan X and Chen K: miR-497 decreases cisplatin resistance
in ovarian cancer cells by targeting mTOR/P70S6K1. Oncotarget.
6:26457–26471. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Panayotopoulou EG, Müller AK, Borries M,
Busch H, Hu G and Lev S: Targeting of apoptotic pathways by SMAC or
BH3 mimetics distinctly sensitizes paclitaxel-resistant triple
negative breast cancer cells. Oncotarget. 8:45088–45104. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen Z, Lin T, Liao X, Li Z, Lin R, Qi X,
Chen G, Sun L and Lin L: Network pharmacology based research into
the effect and mechanism of Yinchenhao Decoction against
Cholangiocarcinoma. Chin Med. 16:132021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hassan MS, Ansari J, Spooner D and Hussain
SA: Chemotherapy for breast cancer (Review). Oncol Rep.
24:1121–1131. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chun KH, Park JH and Fan S: Predicting and
overcoming chemotherapeutic resistance in breast cancer. Adv Exp
Med Biol. 1026:59–104. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Malhotra A, Jain M, Prakash H, Vasquez KM
and Jain A: The regulatory roles of long non-coding RNAs in the
development of chemoresistance in breast cancer. Oncotarget.
8:110671–110684. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li Y, Zhuang W, Huang M and Li X: Long
noncoding RNA DDX11-AS1 epigenetically represses LATS2 by
interacting with EZH2 and DNMT1 in hepatocellular carcinoma.
Biochem Biophys Res Commun. 514:1051–1057. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen D, Chen J, Gao J, Zhang Y, Ma Y, Wei
W and Wei Y: LncRNA DDX11-AS1 promotes bladder cancer occurrence
via protecting LAMB3 from downregulation by sponging miR-2355-5p.
Cancer Biother Radiopharm. 35:319–328. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pang PC, Shi XY, Huang WL and Sun K:
miR-497 as a potential serum biomarker for the diagnosis and
prognosis of osteosarcoma. Eur Rev Med Pharmacol Sci. 20:3765–3769.
2016.PubMed/NCBI
|
|
29
|
Chai L, Kang XJ, Sun ZZ, Zeng MF, Yu SR,
Ding Y, Liang JQ, Li TT and Zhao J: miR-497-5p, miR-195-5p and
miR-455-3p function as tumor suppressors by targeting hTERT in
melanoma A375 cells. Cancer Manag Res. 10:989–1003. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wei XH, Gu XL, Zhou XT, Ma M and Lou CX:
miR-497 promotes the progression of cutaneous squamous cell
carcinoma through FAM114A2. Eur Rev Med Pharmacol Sci.
22:7348–7355. 2018.PubMed/NCBI
|
|
31
|
Zhong H, Yang J, Zhang B, Wang X, Pei L,
Zhang L, Lin Z, Wang Y and Wang C: LncRNA GACAT3 predicts poor
prognosis and promotes cell proliferation in breast cancer through
regulation of miR-497/CCND2. Cancer Biomark. 22:787–797. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bai J, Zhao WY, Li WJ, Ying ZW and Jiang
DQ: Long noncoding RNA LINC00473 indicates a poor prognosis of
breast cancer and accelerates tumor carcinogenesis by competing
endogenous sponging miR-497. Eur Rev Med Pharmacol Sci.
23:3410–3420. 2019.PubMed/NCBI
|
|
33
|
Zhu D, Tu M, Zeng B, Cai L, Zheng W, Su Z
and Yu Z: Up-regulation of miR-497 confers resistance to
temozolomide in human glioma cells by targeting mTOR/Bcl-2. Cancer
Med. 6:452–462. 2017. View
Article : Google Scholar : PubMed/NCBI
|
